Topotecan

• BEACON 2: A Multi-Arm, Multi-Stage Platform Trial For Relapsed Neuroblastoma Pending
  2024-516115-24-00 Phase I/II 10 countries The University Of Birmingham
• A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants with Platinum-Resistant (Part A) and Platinum-Sensitive (Part B… Recruiting
  2025-522255-25-00 Phase III 15 countries Eli Lilly & Co.
• AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer (TREVI-OC-01) Recruiting
  2025-520466-22-00 Phase III 10 countries AstraZeneca AB
• A Phase 3 Study of I-DXd in Subjects with Relapsed SCLC Recruiting
  2023-509628-16-00 Phase III 13 countries Daiichi Sankyo Inc.
• Tarlatamab vs standard of care chemotherapy in patients with pre-treated advanced, pulmonary or gastroenteropancreatic poorly differentiated… Recruiting
  2024-515948-23-00 Phase III 1 country Intergroupe Francophone De Cancerologie Thoracique
• Phase 3, Multicenter, Randomized, Open-label Clinical Study of GSK5764227, a B7-H3 Antibody Drug Conjugate (ADC), compared with Topotecan in… Recruiting
  2025-521627-78-00 Phase III 13 countries Glaxosmithkline Research & Development Limited
• Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator’s Choice in Participants With Platinum Resistant Ovarian Cancer Recruiting
  2024-514822-21-00 Phase III 12 countries Genmab A/S
• Study of Sacituzumab Govitecan Versus Standard of Care in Participants with Previously Treated Extensive Stage Small Cell Lung Cancer Recruiting
  2024-515884-69-00 Phase III 11 countries Gilead Sciences Inc.
• zAvatar test-guided therapeutic decision vs standard of care, in relapsed ovarian cancer and in metastatic breast cancer - A multicentric ra… Recruiting
  2023-509598-22-01 Phase IV 1 country Champalimaud Clinical Centre; Rita Fior
• A Phase 3, Randomized, Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator’s Choice of Treatment i… Recruiting
  2023-508204-38-00 Phase III 9 countries Verastem Inc.
• A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High Grade Ovarian, Primary Peritoneal, or Fallopian Tube Can… Recruiting
  2023-507914-28-00 Phase II/III 9 countries Daiichi Sankyo Inc.
• A Study Evaluating the Overall Survival of Patients with Extensive Stage Small Cell Lung Cancer Receiving Trilaciclib or Placebo prior to To… Recruiting
  2022-502357-34-00 Phase III 8 countries Pharmacosmos A/S
• RETINO 2018: conservative treatment for retinoblastoma: efficacy of the new management strategies and visual outcome Recruiting
  2024-514025-30-00 Phase II 1 country Institut Curie
• Randomized phase III trial on NIraparib-Dostarlimab vs physician’s choice CHEmotherapy in recurrent, ovarian, fallopian tube or primary peri… Recruiting
  2024-516649-38-00 Phase III 4 countries Fondazione Policlinico Universitario Agostino Gemelli IRCCS
• rEECur: International Randomised Controlled Trial of Chemotherapy for the Treatment of Recurrent and Primary Refractory Ewing Sarcoma Recruiting
  2024-516078-31-00 Phase II/III 10 countries The University Of Birmingham
• Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer (DeLLphi-304) Ended
  2022-502669-14-00 Phase III 15 countries Amgen Inc.
• A Phase 2 Study of MORAb-202 in Platinum-resistant High-grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Ended
  2023-504111-33-00 Phase II 3 countries Bristol Myers Squibb International Corporation
• Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed S… Ended
  2024-513559-34-00 Phase III 11 countries Pharma Mar S.A.
• PHASE 1/2 STUDY TO EVALUATE PALBOCICLIB (IBRANCE®) IN COMBINATION WITH IRINOTECAN AND TEMOZOLOMIDE OR IN COMBINATION WITH TOPOTECAN AND CYCL… Ended
  2024-511975-14-00 Phase I/II 5 countries Pfizer Inc.
• A Randomized, Open-Label Trial to Compare Tisotumab Vedotin to Investigator's Choice Chemotherapy in Patients with Cervical Cancer Ended
  2023-503813-31-01 Phase III 13 countries Seagen Inc.
• A study to test Mirvetuximab Soravtansine (IMGN853) aganist doctor's choice of cancer medicines in women with advanced Epithelial Ovarian, P… Ended
  2024-516111-25-00 Phase III 1 country Immunogen Inc.
• BEACON: A randomised phase IIb trial of BEvACizumab added to Temozolomide ± IrinOtecan for children with refractory/relapsed Neuroblastoma Ended
  2024-518931-12-00 Phase II 5 countries The University Of Birmingham
• A study to investigate the efficacy and safety of luveltamab tazevibulin versus IC chemotherapy in women with ovarian cancer (including fall… Ended
  2024-512477-27-00 Phase II 9 countries Sutro Biopharma Inc.

Showing 1–23 of 23 trials